Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today released financial results for the quarter ended December 31, 2025, the third quarter of its 2026 ...

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Ja ...

NOTTINGHAM, United Kingdom, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug ...

SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today ...

Please provide your email address to receive an email when new articles are posted on . Frontotemporal dementia is a rare neurodegenerative disorder that worsens over time. Coya Therapeutics is ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

With a cash buyout price anchoring the stock and orders still hitting records, this move looks less like a macro call and more like a wager on deal certainty and downside protection. NYSE:BEKE: $47.50 ...

An announcement from Abpro Holdings ( (ABP)) is now available. On December 15, 2025, Abpro Holdings, Inc. announced the submission of an investigational new drug (IND) application to the U.S. FDA for ...

BCK Capital opened a new stake in Chart Industries, buying 20,628 shares that accounted for 4.4% of its AUM at the end of Q3. Post-trade, the fund holds 20,628 GTLS shares valued at $4.13 million. The ...

“Our commercial momentum continues, with a third consecutive quarter of sequential orders growth driven by continued strength in our end markets, especially in LNG and data centers as customers are ...